DOCSLIB.ORG

Basics of Antibody Phage Display Technology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Basics of Antibody Phage Display Technology toxins Review Basics of Antibody Phage Display Technology Line Ledsgaard 1, Mogens Kilstrup 1 ID , Aneesh Karatt-Vellatt 2, John McCafferty 2 and Andreas H. Laustsen 1,* ID 1 Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby DK-2800, Denmark; [email protected] (L.L.); [email protected] (M.K.) 2 IONTAS Ltd., Cambridgeshire CB22 3EG, United Kingdom; [email protected] (A.K.-V.); [email protected] (J.M.) * Correspondence: [email protected]; Tel.: +45-2988-1134 Received: 31 May 2018; Accepted: 8 June 2018; Published: 9 June 2018 Abstract: Antibody discovery has become increasingly important in almost all areas of modern medicine. Different antibody discovery approaches exist, but one that has gained increasing interest in the field of toxinology and antivenom research is phage display technology. In this review, the lifecycle of the M13 phage and the basics of phage display technology are presented together with important factors influencing the success rates of phage display experiments. Moreover, the pros and cons of different antigen display methods and the use of naïve versus immunized phage display antibody libraries is discussed, and selected examples from the field of antivenom research are highlighted. This review thus provides in-depth knowledge on the principles and use of phage display technology with a special focus on discovery of antibodies that target animal toxins. Keywords: antibody discovery; recombinant antivenom; phage display; M13 phage; toxinology Key Contribution: Antibody phage display technology is thoroughly presented and discussed in relation to antivenom research and toxinology. 1. Introduction With the recent inclusion of snakebite envenoming on the World Health Organization’s list of Neglected Tropical Diseases [1], focus on both prevention and treatment of this infliction has increased. This creates renewed hope for snakebite victims worldwide and could potentially lead to a mobilization of scientific efforts toward the development of novel snakebite envenoming therapies. Several different avenues aimed at bringing innovation into the field of snakebite antivenoms have been pursued, including medicinal chemistry approaches, novel immunization techniques, and the use of biotechnological strategies [2–5]. One promising approach seems to be the use of human IgG antibodies [6] and/or camelid antibody fragments [7,8], as these molecules can be used to develop recombinant antivenoms with high efficacy and safety due to their compatibility with the human immune system [2]. Moreover, these therapeutic proteins could be manufactured cost-competitively using modern cell cultivation methods employed for large scale production [6,9]. To discover and develop antibodies, different techniques can be harnessed. One approach is phage display selection [10], which is a robust, easy-to-perform, and inexpensive method by which specific antigen binders are selected from large combinatorial libraries containing billions of antibody fragments. As antibody phage display is gaining increasing interest in the field of toxinology, the intention with this review is to provide both basic and more advanced knowledge on the underlying science behind the technology and the lifecycle of the M13 phage. Toxins 2018, 10, 236; doi:10.3390/toxins10060236 www.mdpi.com/journal/toxins Toxins 2018, 10, 236 2 of 15 Toxins 2018, 10, x FOR PEER REVIEW 2 of 15 2. The M13 Bacteriophage 2. TheCentral M13 to Bacteriophage phage display technology is the biology of the bacteriophage used to display antibodies. DifferentCentral bacteriophage to phage systems display cantechnology be utilized is forthe phage biology display, of the including bacteriophage the T4, used lambda, to display as well as theantibodies. filamentous Different M13 bacteriophage bacteriophage [11 systems]. These can different be utilized phage for systems phage eachdisplay, have including their benefits the T4, and drawbacks.lambda, as However, well as the primarily filamentous the M13M13 phagebacteriophage has been [11] utilized. These extensively different phage in recent systems times, each and have to the besttheir of ourbenefits knowledge, and drawbacks. this is the However, only phage primarily system the that M13 has phage been exploredhas been withinutilized toxinology extensively [ 2in,12 ]. Therefore,recent times, this reviewand to the will best focus of our on knowledge, antibody phage this is display the only techniques phage system utilizing that has this been specific explored phage system.within Beforetoxinology giving [2,12] an. in-depth Therefore, description this review of will the stepsfocus involvedon antibody in phagephage displaydisplay experiments,techniques anutilizing introduction this specific to the wild-type phage system. M13 phageBefore isgiving provided. an in-depth description of the steps involved in phageThe display M13 phage experiments, [13] belongs an introduction to a group to the of filamentouswild-type M13 phages phage collectivelyis provided. referred to as Ff phagesThe [14]. M13 The phage Ff phages [13] onlybelongs infect to Escherichiaa group of coli filamentousstrains that phages express collect the Fively pilus referred as the adsorptionto as Ff ofphages the phage [14] to. The the Ff bacterium phages only requires infect Escherichia binding of coli a strains phage that coat express protein the to F the pilus tip as of the the adsorption F pilus [15 ]. Theof M13the phage phage to is the neither bacterium temperate requires nor binding lytic. Instead, of a phage the phagecoat protein establishes to the atip chronic of the infectionF pilus [15] in. its The M13 phage is neither temperate nor lytic. Instead, the phage establishes a chronic infection in its host, where it continuously releases new phages. The phage contains a genome of single-stranded host, where it continuously releases new phages. The phage contains a genome of single-stranded DNA (ssDNA) with a length of 6407 bp [16] that consists of nine genes encoding 11 different proteins. DNA (ssDNA) with a length of 6407 bp [16] that consists of nine genes encoding 11 different proteins. Five of these proteins are coat proteins, and the remaining six proteins are involved in replication Five of these proteins are coat proteins, and the remaining six proteins are involved in replication and assembly of the phage. The M13 phage has a length of 900 nm and a width of 6.5 nm [17]. and assembly of the phage. The M13 phage has a length of 900 nm and a width of 6.5 nm [17]. The Themost most abundant abundant of the of the coat coat proteins proteins is the is thecapsid capsid protein protein G8P, G8P,which which forms forms an envelope an envelope around around the thechromosome chromosome consisting consisting of ofapproximately approximately 2700 2700 protein protein units units (Figure (Figure 1).1 ).The The remaining remaining four four coat coat proteins,proteins, G3P, G3P, G6P, G6P, G7P, G7P, and and G9P, G9P, are are each each present present inin approximatelyapproximately five five copies. copies. Information Information on on the the genesgenes and and proteins proteins of of the the M13 M13 phage phage is is listedlisted inin TableTable1 1.. G 8P G 3P G 7P G 9P + ssD N A G 6P FigureFigure 1. 1.Schematic Schematic representation representation ofof thethe M13M13 bacteriophage, which which is is a afilamentous filamentous phage phage carrying carrying a single-strandeda single-stranded DNA DNA (ssDNA) (ssDNA)chromosome. chromosome. The The genome genome contains contains nine nine genes, genes, which which encode encode 11 11 proteins.proteins. Five Five of of these these proteins proteins are are coat coat proteins proteins (G3P, (G3P, G6P, G6P G7P,, G7P, G8P G8P, and and G9P), G9P), while while the the remaining remainingsix proteinssix proteins are used are used for replication for replication of the of genome,the genome, assembly assembly of theof the phage, phage, and and phage phage extrusion. extrusion. Table 1. Gene name, protein name, protein size, and the function of the genes carried by the M13 Table 1. Gene name, protein name, protein size, and the function of the genes carried by the M13 phage [16]. phage [16]. GeneGene Name Name ProteinProtein Name Name (Abbreviation) (Abbreviation) Size (kDa)Size (kDa) FunctionFunction GeneGene 1 protein 1 protein (G1P) (G1P) 39.639.6 AssemblyAssembly I I GeneGene 11 protein 11 protein (G11P) (G11P) 12.412.4 AssemblyAssembly Replication-associatedReplication-associated protein protein (G2P) (G2P) 46.246.2 ReplicationReplication II II GeneGene 10 protein 10 protein (G10P) (G10P) 12.712.7 ReplicationReplication Coat protein IIIIII AttachmentAttachment protein protein (G3P) (G3P) 44.744.7 Coat protein Adsorption and extrusion Adsorption and extrusion IV IV VirionVirion export exp proteinort protein (G4P) (G4P) 45.945.9 AssemblyAssembly and and extrusion extrusion V V DNA-bindingDNA-binding protein protein (G5P) (G5P) 9.79.7 ReplicationReplication Coat protein VI VI HeadHead virion virion protein protein (G6P) (G6P) 12.412.4 Coat protein Infection and budding Infection and budding VII Tail virion protein (G7P) 3.6 Coat protein Assembly and budding Coat protein VII Tail virion protein (G7P) 3.6 VIII Capsid protein (G8P) 7.6Assembly Coat protein and budding IXVIII Tail virionCapsid protein protein (G9P) (G8P) 3.77.6 Coat protein AssemblyCoat protein and budding Toxins 2018, 10, x FOR PEER REVIEW 3 of 15 Toxins 2018, 10, 236 3 of 15 Coat protein IX Tail virion protein (G9P) 3.7 Assembly and budding The first stage of the M13 infection is the adsorption process, which takes place through binding The first stage of the M13 infection is the adsorption process, which takes place through binding of the N2 domain of the G3P coat protein to the tip of a F pilus on the surface of E. coli hosts of the N2 domain of the G3P coat protein to the tip of a F pilus on the surface of E. coli hosts (Figure (Figure2)[ 18–20]. Under normal conditions, “male” E. coli cells (F+, containing F-pili) appear to trawl 2) [18–20]. Under normal conditions, “male” E.
Load more

Recommended publications
  • Single M13 Bacteriophage Tethering and Stretching
    Single M13 bacteriophage tethering and stretching Ahmad S. Khalil*, Jorge M. Ferrer†, Ricardo R. Brau†, Stephen T. Kottmann‡, Christopher J. Noren§, Matthew J. Lang*†¶, and Angela M. Belcher†¶ʈ Departments of *Mechanical Engineering, †Biological Engineering, ‡Chemistry, and ʈMaterials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; and §New England Biolabs, 240 Country Road, Ipswich, MA 01938 Edited by Robert H. Austin, Princeton University, Princeton, NJ, and approved January 12, 2007 (received for review July 8, 2006) The ability to present biomolecules on the highly organized struc- tightly packaged and contribute little to the WT length of ture of M13 filamentous bacteriophage is a unique advantage. 880–950 nm (7). Where previously this viral template was shown to direct the Control over the composition and assembly of M13 bacterio- orientation and nucleation of nanocrystals and materials, here we phage is not limited to the single-particle level. At critical apply it in the context of single-molecule (SM) biophysics. Genet- concentrations and ionic solution strengths, filamentous bacte- ically engineered constructs were used to display different reactive riophages undergo transitions into various liquid crystalline species at each of the filament ends and along the major capsid, phases (8), which have subsequently been exploited as mac- and the resulting hetero-functional particles were shown to con- roscale templates for organizing nanocrystals (9). These phase sistently tether microscopic beads in solution. With this system, we transitions result from purely entropic effects, typically from the report the development of a SM assay based on M13 bacterio- competition between rotational and translational entropy (10).
    [Show full text]
  • Entry of the Membrane-Containing Bacteriophages Into Their Hosts
    Entry of the membrane-containing bacteriophages into their hosts - Institute of Biotechnology and Department of Biosciences Division of General Microbiology Faculty of Biosciences and Viikki Graduate School in Molecular Biosciences University of Helsinki ACADEMIC DISSERTATION To be presented for public examination with the permission of the Faculty of Biosciences, University of Helsinki, in the auditorium 3 of Info center Korona, Viikinkaari 11, Helsinki, on June 18th, at 8 a.m. HELSINKI 2010 Supervisor Professor Dennis H. Bamford Department of Biosciences University of Helsinki, Finland Reviewers Professor Martin Romantschuk Department of Ecological and Environmental Sciences University of Helsinki, Finland Professor Mikael Skurnik Department of Bacteriology and Immunology University of Helsinki, Finland Opponent Dr. Alasdair C. Steven Laboratory of Structural Biology Research National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health, USA ISBN 978-952-10-6280-3 (paperback) ISBN 978-952-10-6281-0 (PDF) ISSN 1795-7079 Yliopistopaino, Helsinki University Printing House Helsinki 2010 ORIGINAL PUBLICATIONS This thesis is based on the following publications, which are referred to in the text by their roman numerals: I. 6 - Verkhovskaya R, Bamford DH. 2005. Penetration of enveloped double- stranded RNA bacteriophages phi13 and phi6 into Pseudomonas syringae cells. J Virol. 79(8):5017-26. II. Gaidelyt A*, Cvirkait-Krupovi V*, Daugelaviius R, Bamford JK, Bamford DH. 2006. The entry mechanism of membrane-containing phage Bam35 infecting Bacillus thuringiensis. J Bacteriol. 188(16):5925-34. III. Cvirkait-Krupovi V, Krupovi M, Daugelaviius R, Bamford DH. 2010. Calcium ion-dependent entry of the membrane-containing bacteriophage PM2 into Pseudoalteromonas host.
    [Show full text]
  • Using Peptide-Phage Display to Capture Conditional Motif-Based Interactions
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1716 Using peptide-phage display to capture conditional motif-based interactions GUSTAV SUNDELL ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6214 ISBN 978-91-513-0433-5 UPPSALA urn:nbn:se:uu:diva-359434 2018 Dissertation presented at Uppsala University to be publicly examined in B42, BMC, Husargatan 3, Uppsala, Friday, 19 October 2018 at 09:15 for the degree of Doctor of Philosophy. The examination will be conducted in English. Faculty examiner: Doctor Attila Reményi (nstitute of Enzymology, Research Center for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary). Abstract Sundell, G. 2018. Using peptide-phage display to capture conditional motif-based interactions. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 1716. 87 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0433-5. This thesis explores the world of conditional protein-protein interactions using combinatorial peptide-phage display and proteomic peptide-phage display (ProP-PD). Large parts of proteins in the human proteome do not fold in to well-defined structures instead they are intrinsically disordered. The disordered parts are enriched in linear binding-motifs that participate in protein-protein interaction. These motifs are 3-12 residue long stretches of proteins where post-translational modifications, like protein phosphorylation, can occur changing the binding preference of the motif. Allosteric changes in a protein or domain due to phosphorylation or binding to second messenger molecules like Ca2+ can also lead conditional interactions. Finding phosphorylation regulated motif-based interactions on a proteome-wide scale has been a challenge for the scientific community.
    [Show full text]
  • Interactions of Bacteriophages with Animal and Human Organisms—Safety Issues in the Light of Phage Therapy
    International Journal of Molecular Sciences Review Interactions of Bacteriophages with Animal and Human Organisms—Safety Issues in the Light of Phage Therapy Magdalena Podlacha 1 , Łukasz Grabowski 2 , Katarzyna Kosznik-Kaw´snicka 2 , Karolina Zdrojewska 1 , Małgorzata Stasiłoj´c 1 , Grzegorz W˛egrzyn 1 and Alicja W˛egrzyn 2,* 1 Department of Molecular Biology, University of Gdansk, Wita Stwosza 59, 80-308 Gdansk, Poland; [email protected] (M.P.); [email protected] (K.Z.); [email protected] (M.S.); [email protected] (G.W.) 2 Laboratory of Phage Therapy, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Kładki 24, 80-822 Gdansk, Poland; [email protected] (Ł.G.); [email protected] (K.K.-K.) * Correspondence: [email protected]; Tel.: +48-58-523-6024 Abstract: Bacteriophages are viruses infecting bacterial cells. Since there is a lack of specific receptors for bacteriophages on eukaryotic cells, these viruses were for a long time considered to be neutral to animals and humans. However, studies of recent years provided clear evidence that bacteriophages can interact with eukaryotic cells, significantly influencing the functions of tissues, organs, and systems of mammals, including humans. In this review article, we summarize and discuss recent discoveries in the field of interactions of phages with animal and human organisms. Possibilities of penetration of bacteriophages into eukaryotic cells, tissues, and organs are discussed, and evidence of the effects of phages on functions of the immune system, respiratory system, central nervous system, gastrointestinal system, urinary tract, and reproductive system are presented and discussed.
    [Show full text]
  • Development of a Phage Display Library for Discovery of Antigenic Brucella Peptides Jeffrey Williams Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2018 Development of a phage display library for discovery of antigenic Brucella peptides Jeffrey Williams Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Microbiology Commons Recommended Citation Williams, Jeffrey, "Development of a phage display library for discovery of antigenic Brucella peptides" (2018). Graduate Theses and Dissertations. 16896. https://lib.dr.iastate.edu/etd/16896 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Development of a phage display library for discovery of antigenic Brucella peptides by Jeffrey Williams A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Microbiology Program of Study Committee: Bryan H. Bellaire, Major Professor Steven Olsen Steven Carlson The student author, whose presentation of the scholarship herein was approved by the program of study committee, is solely responsible for the content of this thesis. The Graduate College will ensure this thesis is globally accessible and will not permit alterations after a degree is conferred. Iowa State University
    [Show full text]
  • Phage Display Libraries for Antibody Therapeutic Discovery and Development
    antibodies Review Phage Display Libraries for Antibody Therapeutic Discovery and Development Juan C. Almagro 1,2,* , Martha Pedraza-Escalona 3, Hugo Iván Arrieta 3 and Sonia Mayra Pérez-Tapia 3 1 GlobalBio, Inc., 320, Cambridge, MA 02138, USA 2 UDIBI, ENCB, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Casco de Santo Tomas, Delegación Miguel Hidalgo, Ciudad de Mexico 11340, Mexico 3 CONACyT-UDIBI, ENCB, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Colonia Casco de Santo Tomas, Delegación Miguel Hidalgo, Ciudad de Mexico 11340, Mexico * Correspondence: [email protected] Received: 24 June 2019; Accepted: 15 August 2019; Published: 23 August 2019 Abstract: Phage display technology has played a key role in the remarkable progress of discovering and optimizing antibodies for diverse applications, particularly antibody-based drugs. This technology was initially developed by George Smith in the mid-1980s and applied by John McCafferty and Gregory Winter to antibody engineering at the beginning of 1990s. Here, we compare nine phage display antibody libraries published in the last decade, which represent the state of the art in the discovery and development of therapeutic antibodies using phage display. We first discuss the quality of the libraries and the diverse types of antibody repertoires used as substrates to build the libraries, i.e., naïve, synthetic, and semisynthetic. Second, we review the performance of the libraries in terms of the number of positive clones per panning, hit rate, affinity, and developability of the selected antibodies. Finally, we highlight current opportunities and challenges pertaining to phage display platforms and related display technologies.
    [Show full text]
  • Phagemid-Based Method of Producing Filamentous Bacteriophage Particles Displaying Antibody Molecules and the Corresponding Bacteriophage Particles
    Europäisches Patentamt *EP001433846A2* (19) European Patent Office Office européen des brevets (11) EP 1 433 846 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C12N 15/10, C07K 16/00, 30.06.2004 Bulletin 2004/27 C12N 15/62, C12N 7/00, C12N 15/73 (21) Application number: 04005419.9 (22) Date of filing: 10.07.1991 (84) Designated Contracting States: • Griffiths, Andrew David AT BE CH DE DK ES FR GB GR IT LI LU NL SE Cambridge CB1 4AY (GB) • Jackson, Ronald Henry (30) Priority: 10.07.1990 GB 9015198 Cambridge CB1 2NU (GB) 19.10.1990 GB 9022845 • Holliger, Kaspar Philipp 12.11.1990 GB 9024503 Cambridge CB1 4HT (GB) 06.03.1991 GB 9104744 • Marks, James David 15.05.1991 GB 9110549 Kensington, CA 94707-1310 (US) • Clackson, Timothy Piers (62) Document number(s) of the earlier application(s) in Somerville, MA 02143 (US) accordance with Art. 76 EPC: • Chiswell, David John 97120149.6 / 0 844 306 Buckingham MK18 2LD (GB) 96112510.1 / 0 774 511 • Winter, Gregory Paul Cambridge CB2 1TQ (GB) (71) Applicants: • Bonnert, Timothy Peter • Cambridge Antibody Technology LTD Seattle, WA 98102 (US) Cambridge CB1 6GH (GB) • Medical Research Council (74) Representative: Walton, Seán Malcolm et al London W1B 1AL (GB) Mewburn Ellis LLP York House, (72) Inventors: 23 Kingsway • McCafferty, John London WC2B 6HP (GB) Babraham CB2 4AP (GB) • Pope, Anthony Richard Remarks: Cambridge CB1 2LW (GB) This application was filed on 08 - 03 - 2004 as a • Johnson, Kevin Stuart divisional application to the application mentioned Highfields, Cambridge CB3 7NY (GB) under INID code 62.
    [Show full text]
  • Revealing Protein Structures: a New Method for Mapping Antibody Epitopes
    Revealing protein structures: A new method for mapping antibody epitopes Brendan M. Mumey Brian W. Bailey Edward A. Dratz Department of Computer NIH/NlAAA/DlCBWLMBB Department of Chemistry and Science Fluorescence Studies Biochemistry Montana State University Park 5 Building Montana State University Bozeman, MT 59717-3880 12420 Parklawn Dr. MSC Bozeman, MT 59717-3400 [email protected] 8115 [email protected] Bethesda, MD 20892-8115 [email protected] ABSTRACT cells [9] and each protein has a unique folded structure. Whenever A recent idea for determining the three-dimensional structure of a the 3-D folding structure of linear protein sequences can be de- protein uses antibody recognition of surface structure and random termined this information has provided fundamental insights into peptide libraries to map antibody epitope combining sites. Anti- mechanisms of action that are often extremely useful in drug de- bodies that bind to the surface of the protein of interest can be sign. Traditional methods of protein structure determination re- used as “witnesses” to report the structure of the protein as follows: quire preparation of large amounts of protein in functional form, Proteins are composed of linear polypeptide chains that come to- which often may not be feasible. Attempts are then made to grow gether in complex spatial folding patterns to create the native pro- 3-D crystals of the proteins of interest for structure determination tein structures and these folded structures form the binding sites by x-ray diffraction, however, obtaining crystals of sufficient qual- for the antibodies. Short amino acid probe sequences, which bind ity is still an art and may not be possible [24, 251.
    [Show full text]
  • Antibody Discovery for Development of a Serotyping Dengue Virus NS1 Capture Assay
    Antibody Discovery for Development of a Serotyping Dengue Virus NS1 Capture Assay Kebaneilwe Lebani Master of Biotechnology (Advanced) A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2014 Australian Institute for Bioengineering and Nanotechnology ABSTRACT Dengue virus (DENV) infections are a significant public health burden in tropical and sub-tropical regions of the world. Infections are caused by four different but antigenically related viruses which result in four DENV serotypes. The multifaceted nature of DENV pathogenesis hinders the sensitivity of assays designed for the diagnosis of infection. Different markers can be optimally detected at different stages of infection. Of particular clinical importance is the identification of acute viremia during the febrile phase of infection which is pivotal for management of infection. Non-structural protein 1 (NS1) has been identified as a good early surrogate marker of infection with possible applications in epidemiological surveillance and the development of blood screening assays. This contribution is towards using serotype-specificity to achieve specific and more sensitive diagnostic detection of DENV NS1. The general aim of this work is to isolate immune-reagents that can be used to develop an assay with improved sensitivity of DENV NS1 detection in a diagnostic setting. In this work, we sought to isolate serotype-specific antibodies that discern discreet antigenic differences in NS1 from each DENV serotype. Additionally, we also sought to isolate a pairing antibody that recognises NS1 from all four DENV serotypes (pan-reactive) for tandem capture of the DENV NS1. To achieve this, three naive, immunoglobulin gene libraries (a VH domain, a scFv and a Fab library) were interrogated for binders to recombinant NS1 antigen from all four DENV serotypes using phage display technology and various biopanning approaches.
    [Show full text]
  • Monitoramento Em Biotecnologia Desenvolvimento Científico E Tecnológico
    Centro de Gestão e Estudos Estratégicos Ciência, Tecnologia e Inovação Monitoramento em Biotecnologia Desenvolvimento científico e tecnológico 3° Relatório Volume II - Patentes e Países Depositantes Coordenação Adelaide Antunes Rio de Janeiro Março, 2005 MONITORAMENTO EM BIOTECNOLOGIA Desenvolvimento científico e tecnológico 3° Relatório Volume II Patentes e Países Depositantes Executor: Sistema de Informação sobre a Indústria Química (SIQUIM) Escola de Química (EQ) Universidade Federal do Rio de Janeiro (UFRJ) Março / 2005 2 A Biotecnologia tem sido destacada como tecnologia portadora do futuro e consequentemente, com alto componente de desenvolvimento econômico e social, em vários países, principalmente nos últimos anos. O estudo "Monitoramento em Biotecnologia" encomendado pelo CGEE ao SIQUIM/EQ/UFRJ, permite visualizar a dinâmica de P,D&I desta área, a diversidade de atores envolvidos e o forte escopo de atuação em desenvolvimentos que impactam fortemente "Saúde e Qualidade de vida", bem como a "Agricultura e Meio ambiente", por meio de desenvolvimento acelerado de publicações científicas e de patentes nos Temas e/ou Termos tratados neste estudo. Reforça-se, então, que este estudo representa um instrumento importante de apoio à decisão aos stakeholders atuantes na área, pois permite priorizar ações concernentes ao desenvolvimento e estímulo ao uso sustentável da biodiversidade, à segurança biológica e à produção de bioprodutos, biodrogas, transgênicos. Monitoramento em Biotecnologia SIQUIM/EQ/UFRJ e CGEE 3 EQUIPE: Coordenação Geral:
    [Show full text]
  • Molecular Cloning and Functional Expression of Gibberellin 2- Oxidases, Multifunctional Enzymes Involved in Gibberellin Deactivation
    Proc. Natl. Acad. Sci. USA Vol. 96, pp. 4698–4703, April 1999 Plant Biology Molecular cloning and functional expression of gibberellin 2- oxidases, multifunctional enzymes involved in gibberellin deactivation STEPHEN G. THOMAS,ANDREW L. PHILLIPS, AND PETER HEDDEN* Institute of Arable Crops Research (IACR)-Long Ashton Research Station, Department of Agricultural Sciences, University of Bristol, Long Ashton, Bristol BS41 9AF, United Kingdom Communicated by Jake MacMillan FRS, University of Bristol, Bristol, United Kingdom, February 16, 1999 (received for review December 22, 1998) ABSTRACT A major catabolic pathway for the gibberel- centration of bioactive GAs, the genes for these enzymes have lins (GAs) is initiated by 2b-hydroxylation, a reaction cata- not yet been isolated and it has not been possible to study their lyzed by 2-oxoglutarate-dependent dioxygenases. To isolate a regulation. GA 2b-hydroxylase cDNA clone we used functional screening Gibberellin 2b-hydroxylase activity is abundant in seeds of a cDNA library from developing cotyledons of runner bean during the later stages of maturation, particularly in legume (Phaseolus coccineus L.) with a highly sensitive tritium-release seeds, which accumulate large amounts of 2b-hydroxylated b assay for enzyme activity. The encoded protein, obtained by GAs (6–8). Indeed, GA8, the first 2 -hydroxyGA to be heterologous expression in Escherichia coli, converted GA9 to identified, was extracted from seeds of runner bean (Phaseolus b GA51 (2 -hydroxyGA9) and GA51-catabolite, the latter pro- coccineus, originally classified as P. multiflorus) (9). In certain duced from GA51 by further oxidation at C-2. The enzyme thus species, including legumes, further metabolism of 2b- is multifunctional and is best described as a GA 2-oxidase.
    [Show full text]
  • JACK GRIFFITH, Ph
    CURRICULUM VITAE JACK GRIFFITH PERSONAL INFORMATION Home Address: 7515 Kennebec Road Chapel Hill NC 27517 Telephone: 919-966-8563 FAX 919-966-3015 Email address [email protected] Date & Place of Birth: March 26, 1942; Logan, Utah EDUCATION 1964 B.A., Physics, Occidental College, Los Angeles, California. 1969 California Institute of Technology, Biology Department, Ph.D., Biology, (James Bonner, advisor). 1969-1970 Cornell University, Ithaca, New York, Department of Applied Physics, Postdoctoral Fellow, (with Benjamin Siegel). 1970-1973 Stanford University, Stanford, California, Department of Biochemistry, Postdoctoral Fellow, (with Arthur Kornberg). RESEARCH AND PROFESSIONAL EXPERIENCE 1986-present: Full Professor, Lineberger Comprehensive Cancer Center, and Department of Microbiology and Immunology, University of North Carolina at Chapel Hill. 1978-1986: Associate Professor, Lineberger Comprehensive Cancer Center, and Department of Microbiology and Immunology, University of North Carolina at Chapel Hill. 1978-present: Member, Genetics Curriculum, and Program in Molecular Biology and Biotechnology, University of North Carolina at Chapel Hill. 1973-1977: Research Scientist, Biochemistry Department, Stanford University, Stanford, California. 1 PROFESSIONAL SOCIETIES Biophysical Society Associated Societies for Biochemistry and Molecular Biology PROFESSIONAL SERVICE Editorial Boards Journal of Biological Chemistry, 2002-2007 re appointed for 2010-2015 National Review Panels: NIH: Molecular Cytology Study Section: ad Hoc 1985, 1986 NIH: Molecular Biology Study Section: ad hoc 1998 NIH: AIDS/Molecular Biology Study Section: ad hoc 1988 NIH: AIDS/Molecular Biology Study Section: 1989-1994. NIH: AIDS/Molecular Biology Study Section Chair 1992-1994. NIH: Site visit to Albany New York National EM center. Scientific Advisory boards: Board of Scientific Advisors, Brookhaven National Laboratory, 1996-1998 Advisory Board, Fragile X Advocate, 1996-1999.
    [Show full text]